Pieris Pharmaceuticals Announces Milestone Achievement for Boston Pharmaceuticals' Initiation of Phase 1/2 Study of BOS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific
Stock Information for Pieris Pharmaceuticals Inc.
Loading
Please wait while we load your information from QuoteMedia.